Market Place
Sourcing Support
Protara Therapeutics at 44th J.P. Morgan Healthcare Conference
07 Jan 2026 //
GLOBENEWSWIRE
Protara Pharma Gets FDA Breakthrough & Fast Track For TARA-002
05 Jan 2026 //
GLOBENEWSWIRE
Protara Announces Closing of $75 Million Public Offering
08 Dec 2025 //
GLOBENEWSWIRE
Protara Announces Proposed Public Offering
04 Dec 2025 //
GLOBENEWSWIRE
Protara Therapeutics Shares Updated TARA-002 Data
03 Dec 2025 //
GLOBENEWSWIRE
Protara Therapeutics To Review Phase 2 ADVANCED-2 Trial Data
01 Dec 2025 //
GLOBENEWSWIRE
Protara Reports Strong Interim Ph2 STARBORN-1 Data For TARA-002
19 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics To Review Phase 2 STARBORN-1 Trial Data
18 Nov 2025 //
GLOBENEWSWIRE
Protara Presents ADVANCED-2 Trial Data at SUO Meeting
17 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reveals Q3 2025 Financials & Business
10 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics Wins 2026 Biospace Best Places To Work Award
04 Nov 2025 //
GLOBENEWSWIRE
Protara Therapeutics Discloses Inducement Grants Per Nasdaq LR
01 Oct 2025 //
GLOBENEWSWIRE
Protara Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
02 Sep 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Protara Reveals Q2 2025 Financial Results and Business Update
11 Aug 2025 //
GLOBENEWSWIRE
Protara Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Aug 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grants Under Nasdaq
01 Jul 2025 //
GLOBENEWSWIRE
Protara Therapeutics Added to Russell 3000® Index
30 Jun 2025 //
GLOBENEWSWIRE
Protara Therapeutics Appoints William Conkling as CCO
02 Jun 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Join Investor Conferences
13 May 2025 //
GLOBENEWSWIRE
Protara Therapeutics Announces Q1 2025 Results & Business Update
08 May 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grants Under Nasdaq
01 May 2025 //
GLOBENEWSWIRE
Protara Therapeutics Reports Positive Interim Results in Phase 2
26 Apr 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Review Data Ph 2 from TARA-002 Trial
23 Apr 2025 //
GLOBENEWSWIRE
Protara Therapeutics Appoints Leonardo Viana Nicacio, M.D., as CMO
15 Apr 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Present Ph 2 Trial Results at AUA Meeting
10 Apr 2025 //
GLOBENEWSWIRE
Protara Presents THRIVE-1 Data On Choline Deficiency
19 Mar 2025 //
GLOBENEWSWIRE
Protara Therapeutic Announces Q4 & Full Year 2024 Financial Results
05 Mar 2025 //
GLOBENEWSWIRE
Protara Therapeutics To Present At TD Cowen Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
Protara Therapeutic to Present at Oppenheimer Healthcare Conference
05 Feb 2025 //
GLOBENEWSWIRE
Protara Highlights Recent Updates and Anticipated 2025 Milestones
13 Jan 2025 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
Protara Announces Closing of $100 Million Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
Protara Announces Proposed Public Offering
09 Dec 2024 //
GLOBENEWSWIRE
Protara Announces Pricing of $100 Million Public Offering
09 Dec 2024 //
GLOBENEWSWIRE
Protara’s stock doubles biotech divulges new bladder cancer data
06 Dec 2024 //
FIERCE BIOTECH
Protara Shares Positive Results from Ongoing TARA-002 Ph 2 Trial
05 Dec 2024 //
GLOBENEWSWIRE
Protara Therapeutics Hosts Call on Phase 2 ADVANCED-2 Trial Data
03 Dec 2024 //
GLOBENEWSWIRE
Protara to Present Phase 2 ADVANCED-2 Data in NMIBC 25th Meeting
15 Nov 2024 //
GLOBENEWSWIRE
Protara Announces Q3 2024 Results & Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Present at Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Protara Granted FDA Fast Track For Choline Chloride Treatment
21 Oct 2024 //
GLOBENEWSWIRE
Protara Announces Results From THRIVE-1 Study
09 Sep 2024 //
GLOBENEWSWIRE
Protara Completes First Cohort In STARBORN-1 Trial
09 Sep 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Protara Therapeutics Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Protara Therapeutics Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
24 Jun 2024 //
GLOBENEWSWIRE
Protara To Present At Cowen Oncology Innovation Summit
21 May 2024 //
GLOBENEWSWIRE
Protara Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Protara Announces Positive Data from TARA-002 Clinical Program in NMIBC
05 Apr 2024 //
GLOBENEWSWIRE
Protara Announces Align with FDA on Reg Path Forward for IV Choline Chloride
05 Apr 2024 //
GLOBENEWSWIRE
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement
05 Apr 2024 //
GLOBENEWSWIRE
Protara Announces Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Protara to Present at the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Protara Therapeutics to Participate in Upcoming Investor Conferences
31 Jan 2024 //
GLOBENEWSWIRE
Protara Announces Presentation of Data from Phase 1a Trial of TARA-002
30 Nov 2023 //
GLOBENEWSWIRE
Protara Therapeutics Announces Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Protara Announces Dosing of First Patient in Phase 2 Trial of TARA-002
23 Oct 2023 //
GLOBENEWSWIRE
Protara Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial
20 Sep 2023 //
GLOBENEWSWIRE
Protara to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
